Merck Healthcare has announced an agreement to acquire Silence Therapeutics. The deal stage is announced; the companies have not completed the transaction.
The purchase price was not disclosed in the sources.
According to a LinkedIn post from Merck Healthcare, the company described the planned acquisition as part of its effort to strengthen its rare disease pipeline through innovation and strategic investment. The post highlighted Silence Therapeutics' siRNA therapy, Divesiran, and said the deal represents another step toward addressing unmet patient needs in specialty and rare diseases.
The source did not provide further details on the terms, the structure of the transaction, or a expected closing date.